Pci Biotech Holding Asa · LSE:0JGL
Pci Biotech Holding Asa — Q1 2023 Earnings Presentation
12 slides from Pci Biotech Holding Asa's earnings presentation, May 12, 2023
Slide 1: PCI Biotech - Q1 2023 Interim Report
PCI Biotech - Q1 2023 Interim Report Presentation May 12, 2023 Ronny Skuggedal, CEO / CFO Anders Høgset, CSO Morten Luhr, BD Manager www.pcibiotech.com
Slide 2: Important notice and disclaimer
PCI Biotech Important notice and disclaimer This presentation may contain certain forward-looking Factors that could cause these differences include, but are not limited to, statements and forecasts based on uncertainty, since they implementation of PCI Biotech’s strategy and its ability to further
Slide 3: Table of Contents
Table of Contents Highlights Operational review Key financials Outlook Q&A www.pcibiotech.com 3
Slide 4: Highlights Q1 2023: fimaNAC
Highlights Q1 2023 fimaNAC fimaNAC for use in gene therapy manufacturing Bioprocessing First patent application filed 2H 2022 • New results generated Q1 2023 that add to the initial application Value proposition • Positive initial external feedback reiterated in Q1 2023 • Focus on generating r
Slide 5: Highlights Q1 2023: fimaVACC and Corporate
Highlights Q1 2023 fimaVACC ► Exploring approaches aiming to identify novel immunotherapy combinations Intratumoural A patent application for an undisclosed treatment approach filed Q1 2023 immunotherapy Ph.D. candidate grant of up to NOK 2.5 million over 3 years, commencing Q1 2023 Corporate
Slide 6: Operational review
Operational review 6
Slide 7: fimaNAC: Platform technology for delivery of nucleic acids to skin
Platform technology for delivery of nucleic acids to skin fimaNAC Background Operational Many skin conditions with large unmet medical needs can potentially be treated with nucleic acid based therapies review – E.g. chronic ulcers, inflammatory diseases, inherited diseases Dermatology Ineffici
Slide 8: fimaNAC: Maximising yield in gene therapy manufacturing
fimaNAC Maximising yield in gene therapy manufacturing Operational review – Bioprocessing fimaNAc addresses technical needs in manufacturing of gene therapies New data generated in Q1 has strengthened patent submitted 2H 2022 Maintain focus on expanding IP through the 12-month priority period and ge
Slide 9: Key financials, Outlook, Q&A
Key financials Outlook Q&A (On
Slide 10: Finance: Key financial figures
Finance ► Financial run-way estimated towards the end of 2024 Cash position of NOK 51 million per end of Q1 2023 Restructuring in 2022 makes comparison with last year figures irrelevant Key financial SkatteFUNN grant application submitted for 2023-2025 figures (figures in NOK 1 000) Q1 2023 Q1
Slide 11: Outlook: 1H 2023 Milestones
Outlook Leveraging the PCI technology platform within bioprocessing, dermatology, and immunotherapy Pipeline 1H 2023 Milestones Status milestones 1H 2023 1H 2023 Milestones • Submit patent for novel intratumoural immunotherapy approach Laying the ground for • Submit patent on refined sea lice combat
Slide 12: PCI Biotech: For enquiries
Enabling intracellular PCI Biotech delivery For enquiries: Ronny Skuggedal, CEO / CFO Mobile phone: +47 940 05 757 E-mail: rs@pcibiotech.com www.pcibiotech.com 12